Article Figures & Data
Figures
- FIGURE 1.
99mTc-etarfolatide biodistribution pattern (1 h after injection) after folate preinjection in healthy volunteers. In absence of folate preinjection, 99mTc-etarfolatide uptake is seen in liver, kidney, spleen, bladder, and bone marrow. This background organ activity is decreased with preinjected folate.
- FIGURE 2.
(A) Whole-body planar images obtained approximately 1 h after 99mTc-etarfolatide administration in lung cancer patient. (B) 99mTc-etarfolatide SPECT images were manually fused to patient’s prior CT images. SPECT/CT transaxial fusion images delineate tumor in left lower lobe (single arrow), with diffuse pleural spread of tumor and pericardial metastasis (triple arrows). 99mTc-etarfolatide uptake in inflammatory lesions such as benign osteophytes can be seen (double arrows).
- FIGURE 3.
(A) Whole-body planar 99mTc-etarfolatide study for known pulmonary nodule obtained approximately 1 h after 99mTc-etarfolatide administration. As with other imaging agents, planar 2-dimensional imaging lacks image contrast and sensitivity for detecting 99mTc-etarfolatide binding to small pulmonary nodule in left lower lobe. (B) 99mTc-etarfolatide SPECT images with maximum intensity projection (upper right), transaxial (upper left), sagittal (lower left), and coronal (lower right) were manually fused to patient’s prior CT images, allowing for better anatomic localization and confirmation of FR binding to pulmonary nodule in this biopsy-proven non–small cell lung cancer.
